

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1611

BAULCH-BROWN ET AL.

Examiner: Sznaidman, Marcos L.

APPLICATION NO: 10/526,282

FILED: FEBRUARY 16, 2006

FOR: COMBINATION THERAPY COMPRISING A BISPHOSPHONATE
AND A HMG-COA REDUCTASE INHIBITOR

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of December 5, 2008 has a shortened statutory time set to expire on March 5, 2009. A two-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$490 for payment of the extension fee. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080

Date: 4/28/09



Oona A. Manzari
Attorney for Applicants
Reg. No. 48,152
Phone No. (862) 778-7852